Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAM-MS: HSCT vs Standard Therapy in RRMS
NCT03477500Phase 3Active, not recruiting
- Sponsor
- Haukeland University Hospital
- Start
- Mar 2018
- Primary completion
- Nov 2026
- Modality
- Stem Cell Therapies
- Countries
- 4
01
Overview
A Phase 3 trial of autologous hematopoietic stem cells in relapsing-remitting multiple sclerosis (RRMS), sponsored by Haukeland University Hospital. Started Mar 2018; status: active, not recruiting.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03477500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03477500.